Cuorips Inc. Logo

Cuorips Inc.

Develops iPS cell-derived therapies and provides cell processing contract services.

4894 | T

Overview

Corporate Details

ISIN(s):
JP3266030000
LEI:
Country:
Japan
Address:
中央区日本橋本町三丁目11番5号 日本橋ライフサイエンスビルディング2、507

Description

Cuorips Inc. is a regenerative medicine company that originated as a spin-off from Osaka University. The company specializes in the research, development, and commercialization of cellular and tissue-based products derived from induced pluripotent stem (iPS) cells. Its primary product is a cardiac myocyte sheet, a novel therapy developed for treating severe heart failure. This cardiac tissue sheet, created from iPS cells, is designed to be grafted onto a patient's heart to restore function. In addition to its proprietary product pipeline, Cuorips provides contract services for the development and manufacturing of cell processing products, contributing to the advancement of medical care through cutting-edge technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:13
確認書
Japanese 8.1 KB
2025-11-13 08:07
半期報告書-第10期(2025/04/01-2026/03/31)
Japanese 199.3 KB
2025-06-25 08:39
臨時報告書
Japanese 22.9 KB
2025-06-20 08:39
確認書
Japanese 8.1 KB
2025-06-20 08:38
内部統制報告書-第9期(2024/04/01-2025/03/31)
Japanese 21.5 KB
2025-06-20 08:37
有価証券報告書-第9期(2024/04/01-2025/03/31)
Japanese 2.3 MB
2024-11-14 02:30
確認書
Japanese 8.1 KB
2024-11-14 02:24
半期報告書-第9期(2024/04/01-2025/03/31)
Japanese 162.2 KB
2024-07-01 02:38
臨時報告書
Japanese 22.2 KB
2024-06-27 09:38
内部統制報告書-第8期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:37
確認書
Japanese 8.1 KB
2024-06-27 09:36
有価証券報告書-第8期(2023/04/01-2024/03/31)
Japanese 2.9 MB
2024-02-13 07:36
確認書
Japanese 8.1 KB
2024-02-13 07:36
四半期報告書-第8期第3四半期(2023/10/01-2023/12/31)
Japanese 132.3 KB
2023-11-10 08:29
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all Cuorips Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cuorips Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cuorips Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.